BCEIE › News › SANOFI

Dividend

Sanofi India: Communication of Tax Deduction at Source on Interim Dividend for the Financial Year 2026

Sanofi India (SANOFI) filed a disclosure titled "Communication of Tax Deduction at Source on Interim Dividend for the Financial Year 2026". The company is valued at about ₹7,346 crore.

BCEIE News Desk · Published 29 Oct 2026, 09:33 pm IST · Filing received 29 Oct 2026, 09:18 pm IST

What happened

Sanofi India (SANOFI) filed a disclosure with the exchanges on 29 October 2026 at 09:18 PM titled "Communication of Tax Deduction at Source on Interim Dividend for the Financial Year 2026".

From the filing: "Sanofi India Limited has informed the Exchange about Communication of Tax Deduction at Source on Interim Dividend for the Financial Year 2026"

Company snapshot

Sanofi India is a small-cap company, with a market value of about ₹7,346 crore.

The stock last traded at ₹3,189.5, against a 52-week range of ₹2,758.2–₹4,898 (34.9% below the high).

Before this filing the shares had moved −4.7% over the month and −12.5% over three months. Average daily turnover over the last 20 sessions was about ₹4.51 crore.

Promoters held 60.40% at the end of Q1 FY27. Foreign institutions owned 5.69% and domestic institutions 19.87%.

Quarterly results (standalone, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q1 FY2640669.530.18
Q2 FY264757632.99
Q3 FY2642061.726.79
Q4 FY26472102.644.55
Q1 FY2743883.536.26

What history shows

This is not the company's first dividend disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.

Market-wide, 915 dividend filings with an impact score of 50 or more saw an average next-day move of +0.0%, with 43% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

  • 29 October 2026: Board meeting — Financial Results/Dividend.

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.

More on Sanofi India Limited